HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rises more than 3%. The application for the marketing approval of Haiqu Ebulesine tablets has been accepted by the National Medical Products Administration.

Jiangsu Hengrui Pharmaceuticals (01276) rose more than 3% as of the time of publication, up 3.19% to HK$77.75, with a trading volume of HK$146 million. On the news front, Jiangsu Hengrui Pharmaceuticals announced that the company recently received a "Notice of Acceptance" issued by the National Medical Products Administration. The company's Haiqu Bopapa Ethanolamine tablets have had their drug marketing approval application accepted by the National Medical Products Administration, with indications for use in adult and pediatric patients aged 6 and above with persistent and chronic primary immune thrombocytopenia (ITP) who have had inadequate responses to previous treatment with glucocorticoids, immunoglobulins, etc. In March 2025, the Phase III clinical trial of Haiqu Bopapa Ethanolamine tablets (HR-TPO-ITP-III-PED) reached the pre-defined primary research endpoints. This study is a multicenter, randomized, double-blind, and open-label Phase III study to evaluate the effectiveness and safety of Haiqu Bopapa Ethanolamine tablets in pediatric and adolescent patients with primary immune thrombocytopenia, conducted by Professor Wang Tianyou of Beijing Children's Hospital, Capital Medical University, with a total of 100 patients aged 6 and above. The treatment group showed significant improvement over the control group in the primary endpoints, and long-term treatment was found to be safe and effective.